# To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications

Study · id `cardio:ct-nct06467513` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06467513](<https://clinicaltrials.gov/study/NCT06467513>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06467513

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 102 participants.

## Technical summary

Registry record NCT06467513. Randomized; triple masking; primary purpose other. Start 2024-01-01 (actual); primary completion 2025-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose other
- Phase: Phase 4
- Enrolled: 102 participants (planned count; ClinicalTrials.gov record NCT06467513, source copy `cardio:ctgov-nct06467513-2024-06-21`, retrieved 2026-10-26)
- Started: 2024-01-01 (actual) (ClinicalTrials.gov record NCT06467513, source copy `cardio:ctgov-nct06467513-2024-06-21`, retrieved 2026-10-26)
- Primary completion: 2025-05 (anticipated) (ClinicalTrials.gov record NCT06467513, source copy `cardio:ctgov-nct06467513-2024-06-21`, retrieved 2026-10-26)
- Completion: 2025-05 (anticipated) (ClinicalTrials.gov record NCT06467513, source copy `cardio:ctgov-nct06467513-2024-06-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06467513, source copy `cardio:ctgov-nct06467513-2024-06-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06467513-2024-06-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications
- Condition: Heart Diseases
- Condition: Heart Valve Diseases
- Intervention (Drug): Esketamine hydrochloride injection
- Lead sponsor: Zhang XIao Mei
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 6def3ee340c057bf142070a38e8c35d612a69b61a4dde33e1a6f95b0f12a7f37
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
